Improving the evaluation of new cancer treatments: challenges and opportunities.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12671669.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?
Medical subject headings
- Antineoplastic Agents
- Clinical Trials as Topic
- Neoplasms
- Research Design